REPARE THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.15 USD | +4.30% |
|
-9.22% | -56.85% |
Financials (USD)
| Sales 2024 * | 45.21M | Sales 2025 * | 11.79M | Capitalization | 127M |
|---|---|---|---|---|---|
| Net income 2024 * | -116M | Net income 2025 * | -171M | EV / Sales 2024 * | -2.26 x |
| Net cash position 2024 * | 229M | Net cash position 2025 * | 325M | EV / Sales 2025 * | -16.8 x |
| P/E ratio 2024 * |
-1.13
x | P/E ratio 2025 * |
-0.96
x | Employees | 179 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.95% |
More Fundamentals
* Assessed data
More news
Latest transcript on Repare Therapeutics Inc.
More recommendations
More press releases
More news
| 1 day | +4.30% | ||
| 1 week | -13.70% | ||
| Current month | -33.12% | ||
| 1 month | -39.89% | ||
| 3 months | -48.70% | ||
| 6 months | -30.31% | ||
| Current year | -56.85% |
1 week
2.98
3.71
1 month
2.985.52
Current year
2.988.49
1 year
2.9813.85
3 years
2.9835.75
5 years
2.9846.44
10 years
2.9846.44
| Managers | Title | Age | Since |
|---|---|---|---|
Lloyd Segal
CEO | Chief Executive Officer | 60 | 16-05-31 |
Steve Forte
DFI | Director of Finance/CFO | 45 | 19-09-30 |
Michael Zinda
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | 19-02-28 |
Lloyd Segal
CEO | Chief Executive Officer | 60 | 16-05-31 |
Ann Rhoads
BRD | Director/Board Member | 58 | 20-06-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.33% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 3.02 | -5.92% | 140,289 |
| 24-04-17 | 3.21 | -3.89% | 79,291 |
| 24-04-16 | 3.34 | -3.75% | 85,215 |
| 24-04-15 | 3.47 | -4.93% | 89,849 |
| 24-04-12 | 3.65 | -6.41% | 94,321 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Companyâs initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.02
USD
Average target price
15.33
USD
Spread / Average Target
+407.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -56.85% | 127M | |
| -1.42% | 41.35B | |
| +42.15% | 40.38B | |
| +1.97% | 39.05B | |
| -14.19% | 26.67B | |
| +1.82% | 24.07B | |
| -24.55% | 18.36B | |
| -4.07% | 11.68B | |
| +21.36% | 11.6B | |
| +8.20% | 11.15B |
- Stock Market
- Equities
- RPTX Stock
